149 related articles for article (PubMed ID: 9845102)
1. Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study.
Lee DJ; Trotti A; Spencer S; Rostock R; Fisher C; von Roemeling R; Harvey E; Groves E
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):811-5. PubMed ID: 9845102
[TBL] [Abstract][Full Text] [Related]
2. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Lee DJ; Cosmatos D; Marcial VA; Fu KK; Rotman M; Cooper JS; Ortiz HG; Beitler JJ; Abrams RA; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):567-76. PubMed ID: 7790241
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer.
Rischin D; Peters L; Hicks R; Hughes P; Fisher R; Hart R; Sexton M; D'Costa I; von Roemeling R
J Clin Oncol; 2001 Jan; 19(2):535-42. PubMed ID: 11208848
[TBL] [Abstract][Full Text] [Related]
4. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
6. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
Rischin D; Peters LJ; O'Sullivan B; Giralt J; Fisher R; Yuen K; Trotti A; Bernier J; Bourhis J; Ringash J; Henke M; Kenny L
J Clin Oncol; 2010 Jun; 28(18):2989-95. PubMed ID: 20479425
[TBL] [Abstract][Full Text] [Related]
7. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Haas ML; Conley BA; Egorin MJ; Levy S; Sivasailam S; Herman JM; Jacobs MC; Gray WC; Ord RA; Aisner JA; Van Echo DA
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):49-56. PubMed ID: 10758304
[TBL] [Abstract][Full Text] [Related]
8. Intensification regimen 2 for advanced head and neck squamous cell carcinomas.
Grecula JC; Schuller DE; Rhoades CA; Au JL; Nag S; Bauer CJ; Agrawal A; Martinez-Monge R; Johnson A; Young D; Gahbauer RA
Arch Otolaryngol Head Neck Surg; 1999 Dec; 125(12):1313-8. PubMed ID: 10604408
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
Cohen EE; Rosine D; Haraf DJ; Loh E; Shen L; Lusinchi A; Vokes EE; Bourhis J
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):678-84. PubMed ID: 17293229
[TBL] [Abstract][Full Text] [Related]
10. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma.
de Castro G; Snitcovsky IM; Gebrim EM; Leitão GM; Nadalin W; Ferraz AR; Federico MH
Eur Arch Otorhinolaryngol; 2007 Dec; 264(12):1475-82. PubMed ID: 17643256
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
12. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
13. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme.
Del Rowe J; Scott C; Werner-Wasik M; Bahary JP; Curran WJ; Urtasun RC; Fisher B
J Clin Oncol; 2000 Mar; 18(6):1254-9. PubMed ID: 10715295
[TBL] [Abstract][Full Text] [Related]
14. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
[TBL] [Abstract][Full Text] [Related]
15. High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck.
Regine WF; Valentino J; Arnold SM; Haydon RC; Sloan D; Kenady D; Strottmann J; Pulmano C; Mohiuddin M
J Clin Oncol; 2001 Jul; 19(14):3333-9. PubMed ID: 11454880
[TBL] [Abstract][Full Text] [Related]
16. Role of concomitant chemoradiation in locally advanced head and neck cancers.
Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
[TBL] [Abstract][Full Text] [Related]
17. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
18. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
[TBL] [Abstract][Full Text] [Related]
19. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24.
Al-Sarraf M; Pajak TF; Byhardt RW; Beitler JJ; Salter MM; Cooper JS
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):777-82. PubMed ID: 9128951
[TBL] [Abstract][Full Text] [Related]
20. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Rischin D; Peters L; Fisher R; Macann A; Denham J; Poulsen M; Jackson M; Kenny L; Penniment M; Corry J; Lamb D; McClure B
J Clin Oncol; 2005 Jan; 23(1):79-87. PubMed ID: 15625362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
